Autolus Therapeutics (AUTL)
1.65
0.00 (0.00%)
At close: Mar 28, 2025, 3:59 PM
1.74
5.45%
After-hours: Mar 28, 2025, 05:38 PM EDT
0.00% (1D)
| Bid | 1.66 |
| Market Cap | 439.11M |
| Revenue (ttm) | 10.55M |
| Net Income (ttm) | -230.14M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -1.92 |
| Forward PE | -2.66 |
| Analyst | Strong Buy |
| Ask | 1.8 |
| Volume | 654,687 |
| Avg. Volume (20D) | 1,265,455.1 |
| Open | 1.65 |
| Previous Close | 1.65 |
| Day's Range | 1.63 - 1.70 |
| 52-Week Range | 1.56 - 6.31 |
| Beta | 2.06 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a program...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2018
Employees 647
Stock Exchange NASDAQ
Ticker Symbol AUTL
Website https://www.autolus.com
Analyst Forecast
According to 5 analyst ratings, the average rating for AUTL stock is "Strong Buy." The 12-month stock price forecast is $10, which is an increase of 506.06% from the latest price.
Stock Forecasts1 week ago
-13.4%
Autolus Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
10 months ago
+7.86%
Autolus Therapeutics shares are trading higher. The company reported Q1 financial results.
